Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SYNAPSE BIOMEDICAL EUROPE : revenue, balance sheet and financial ratios

SYNAPSE BIOMEDICAL EUROPE is a French company founded 18 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in ENGHIEN-LES-BAINS (95880), this company of category PME shows in 2019 a net income positive of 308 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SYNAPSE BIOMEDICAL EUROPE (SIREN 501840847)
Indicator 2019
Revenue N/C
Net income 307 561 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2019, SYNAPSE BIOMEDICAL EUROPE generates positive net income of 308 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2019) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

307 561 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 273340%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 0%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2019) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

273339.56%

Financial autonomy (2019) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

0.035%

Asset age ratio (2019) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

9.2%

Solvency indicators evolution
SYNAPSE BIOMEDICAL EUROPE

Sector positioning

Debt ratio
273339.56 2019
2019
Q1: 0.0
Med: 5.81
Q3: 50.5
Watch

In 2019, the debt ratio of SYNAPSE BIOMEDICAL EUROPE (273339.56) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
0.04% 2019
2019
Q1: 13.07%
Med: 37.67%
Q3: 60.35%
Watch

In 2019, the financial autonomy of SYNAPSE BIOMEDICAL EUROPE (0.0%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 2390.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2019) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

2390.651

Liquidity indicators evolution
SYNAPSE BIOMEDICAL EUROPE

Sector positioning

Liquidity ratio
2390.65 2019
2019
Q1: 130.25
Med: 196.66
Q3: 322.59
Excellent

In 2019, the liquidity ratio of SYNAPSE BIOMEDICAL EUROPE (2390.65) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Positioning of SYNAPSE BIOMEDICAL EUROPE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 79 011€ to 3 740 769€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2019
Indicative
79k€ 205k€ 3740k€
205 208 € Range: 79 011€ - 3 740 769€
NAF 5 année 2019
How is this estimate calculated?

This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare SYNAPSE BIOMEDICAL EUROPE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about SYNAPSE BIOMEDICAL EUROPE

What is the revenue of SYNAPSE BIOMEDICAL EUROPE ?

The revenue of SYNAPSE BIOMEDICAL EUROPE is not publicly disclosed (confidential accounts filed with INPI).

Is SYNAPSE BIOMEDICAL EUROPE profitable?

Yes, SYNAPSE BIOMEDICAL EUROPE generated a net profit of 308 k€ in 2019.

Where is the headquarters of SYNAPSE BIOMEDICAL EUROPE ?

The headquarters of SYNAPSE BIOMEDICAL EUROPE is located in ENGHIEN-LES-BAINS (95880), in the department Val-d'Oise.

Where to find the tax return of SYNAPSE BIOMEDICAL EUROPE ?

The tax return of SYNAPSE BIOMEDICAL EUROPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SYNAPSE BIOMEDICAL EUROPE operate?

SYNAPSE BIOMEDICAL EUROPE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.